Targeting histone deacetylases for heart diseases.
HDACs
Heart diseases
Inhibitors
Journal
Bioorganic chemistry
ISSN: 1090-2120
Titre abrégé: Bioorg Chem
Pays: United States
ID NLM: 1303703
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
03
03
2023
revised:
17
04
2023
accepted:
05
05
2023
medline:
10
7
2023
pubmed:
25
5
2023
entrez:
24
5
2023
Statut:
ppublish
Résumé
Histone deacetylases (HDACs) are responsible for the deacetylation of lysine residues in histone or non-histone substrates, leading to the regulation of many biological functions, such as gene transcription, translation and remodeling chromatin. Targeting HDACs for drug development is a promising way for human diseases, including cancers and heart diseases. In particular, numerous HDAC inhibitors have revealed potential clinical value for the treatment of cardiac diseases in recent years. In this review, we systematically summarize the therapeutic roles of HDAC inhibitors with different chemotypes on heart diseases. Additionally, we discuss the opportunities and challenges in developing HDAC inhibitors for the treatment of cardiac diseases.
Identifiants
pubmed: 37224740
pii: S0045-2068(23)00262-6
doi: 10.1016/j.bioorg.2023.106601
pii:
doi:
Substances chimiques
Histone Deacetylases
EC 3.5.1.98
Histone Deacetylase Inhibitors
0
Histones
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
106601Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.